Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions

被引:17
|
作者
Sugaya, Nobuyoshi [1 ]
Furuya, Toshio [1 ]
机构
[1] PharmaDesign Inc, Div Res & Dev, Drug Discovery Dept, Chuo Ku, Tokyo, Japan
来源
BMC BIOINFORMATICS | 2011年 / 12卷
关键词
INTERACTION INHIBITORS; INTERACTION NETWORK; SMALL MOLECULES; TARGET; CLASSIFICATION; KNOWLEDGEBASE; RECOGNITION; INFORMATION; INTERFACES; DISCOVERY;
D O I
10.1186/1471-2105-12-50
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: The amount of data on protein-protein interactions (PPIs) available in public databases and in the literature has rapidly expanded in recent years. PPI data can provide useful information for researchers in pharmacology and medicine as well as those in interactome studies. There is urgent need for a novel methodology or software allowing the efficient utilization of PPI data in pharmacology and medicine. Results: To address this need, we have developed the 'Druggable Protein-protein Interaction Assessment System' (Dr. PIAS). Dr. PIAS has a meta-database that stores various types of information (tertiary structures, drugs/chemicals, and biological functions associated with PPIs) retrieved from public sources. By integrating this information, Dr. PIAS assesses whether a PPI is druggable as a target for small chemical ligands by using a supervised machine-learning method, support vector machine (SVM). Dr. PIAS holds not only known druggable PPIs but also all PPIs of human, mouse, rat, and human immunodeficiency virus (HIV) proteins identified to date. Conclusions: The design concept of Dr. PIAS is distinct from other published PPI databases in that it focuses on selecting the PPIs most likely to make good drug targets, rather than merely collecting PPI data.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] How Many Protein-Protein Interactions Types Exist in Nature?
    Garma, Leonardo
    Mukherjee, Srayanta
    Mitra, Pralay
    Zhang, Yang
    PLOS ONE, 2012, 7 (06):
  • [22] AAA ATPase protein-protein interactions as therapeutic targets in cancer
    Mannar, Dhiraj
    Ahmed, Sana
    Subramaniam, Sriram
    CURRENT OPINION IN CELL BIOLOGY, 2024, 86
  • [23] Computational probing protein-protein interactions targeting small molecules
    Wang, Yong-Cui
    Chen, Shi-Long
    Deng, Nai-Yang
    Wang, Yong
    BIOINFORMATICS, 2016, 32 (02) : 226 - 234
  • [24] Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach
    Abdel-Rahman, Noha
    Martinez-Arias, Alfonso
    Blundell, Tom L.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 1327 - 1333
  • [25] Recent Trends in QSAR in Modelling of Drug-Protein and Protein-Protein Interactions
    Sharma, Smriti
    Bhatia, Vinayak
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2021, 24 (07) : 1031 - 1041
  • [26] Inhibitors of protein-protein interactions as potential drugs
    Veselovsky, Alexander V.
    Archakov, Alexander I.
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2007, 3 (01) : 51 - 58
  • [27] Computational Resources for Predicting Protein-Protein Interactions
    Tanwar, Himani
    Doss, C. George Priya
    PROTEIN-PROTEIN INTERACTIONS IN HUMAN DISEASE, PT A, 2018, 110 : 251 - 275
  • [28] PlaPID: a database of protein-protein interactions in plants
    Min, Mingwei
    Cai, Haoyang
    Zheng, Wen
    Yang, Zhirui
    Li, Xiao
    Fan, Xinjian
    Feng, Quansheng
    2010 4TH INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING (ICBBE 2010), 2010,
  • [29] ProteinPrompt: a webserver for predicting protein-protein interactions
    Canzler, Sebastian
    Fischer, Markus
    Ulbricht, David
    Ristic, Nikola
    Hildebrand, Peter W.
    Staritzbichler, Rene
    BIOINFORMATICS ADVANCES, 2022, 2 (01):
  • [30] Targeting protein-protein interactions as an anticancer strategy
    Ivanov, Andrei A.
    Khuri, Fadlo R.
    Fu, Haian
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (07) : 393 - 400